Secured $76.8 Million Verdict on Behalf of Health Insurers in Direct Action Alleging Unlawful Monopolization of Prescription Drugs
August 29, 2017
In re: Lorazepam & Clorazepate Antitrust Litigation, 99-mc-00276 (D.D.C.)
Robins Kaplan secured a $76.8 million jury verdict on behalf of three health insurers that allegedly overpaid for prescription drugs because of a branded manufacturer’s anticompetitive exclusion of generic competition through the restriction of the generics’ supply of active pharmaceutical ingredients.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.